I have come across a great website called curezone.com which has a free exchange of medical information, debate and personal stories on possible ‘cures’ on all kinds of illnesses.
There is an amazing section on an apparent cure for HIV and AIDS called Imusil/Tetrasil – see http://curezone.com/dis/1.asp?CO=24
From what I can gather Tetrasil is a silver compound for external use, which seems to treat many kinds of skin conditions like Psoriasis, Eczmae – see http://www.tetrasil.com. Imusil is Tetrasil but in an injectable form – this is apparently the one-off injection ‘cure’ HIV/AIDS.
It is a compound of silver Ag.sub.40.sub.4 – quite a simple compound by all accounts. A man called Boyd E Graves was diagnosed with HIV in the 1970’s and searched for a cure. He eventually came across this Tetrasil and Imusil and had a one off injection of Imusil that apparently cured him.
Boyd Graves came across a document by the US Government which appears to be conclusive proof that AIDS/HIV was a virus developed by the US government in a population cull of the black people.
The information he uncovered was a flow chart, charting the development of what the US government called the Special Virus Project – see http://www.boydgraves.com’flowchart/ . Boyd Davis said that the chart has been independently verified by a dozen doctors who confirmed that HIV/AIDS is in fact man-made.
Tetrasil and Imusil has been patented in the US by a DR Marvin Antelman. I found the following information on Antelman’s Compassionresponsenetwork.com website.
Treatment of AIDS
From an article, Antiviral Tetrasilver Tetroxide Therapy, by Dr Marvin S Antelman. The full 5-page article is available through Dr Antelman or Compassion Response Network.
AIDS-Non Terminal Patients: “Clinical testing was performed at Exetec Lab, SA in Honduras under the supervision of Dr. L Roland Valenzuela. Thirty patients were selected from three etiological AIDS groups, 10 for each group namely, Candidiasis, Wasting Syndrome and p. carinii pneumonia. Each patient was given an intravenous infusion of Imusil administered over a three hour period. All patients experienced temperature elevation within 48 hours of administering the Imusil, which was indicative that the immune system was now functioning along with the fact that all patients also started to have dramatic increases in their white blood cell counts. At the end of 30 days of observation, all patients were cured of AIDS. All patients presenting Wasting Syndrome were completely cured of the Syndrome; the average patient gaining approximately one half pound per day. Three patients were completely cured of their pneumonia. Because the protocol was changed from direct injection to slow i.v. infusion of the Imusil, there were no side effects of hepatomegaly.”
On the ‘curezone’ website there is a lot of very interesting claims made. That Tetrasil/Imusil is a cure for all pathogen related diseases, like cancer and that it is the cure for Gulf War disease.
Status: In independent testing, HIV, the virus that causes AIDS (Acquired Immune Deficiency Syndrome) was destroyed (98.4%) in-vitro with concentrations as low as 20 parts-per-million. Toxicity analysis in-vitro and in mice showed that the company’s Tetrasilver Tetroxide (TST) does not produce toxic side effects and that healthy tissues are not effected. Because of documented non-toxicity, a limited number of terminally ill AIDS patients suffering from Wasting Syndrome, Candidiasis and P. Carinii Pneumonia have been treated in clinics outside the US. Thirty days after treatment, clinics reported an increase in patient body weight, white blood cells and other key markers.
Because TST is a broad-spectrum anti-pathogen, when administered to AIDS patients it apparently destroys many of the opportunistic infectious diseases that usually accompany HIV/AIDS.
Laboratory and clinical analysis has also documented the ability of TST to destroy the Herpes Simplex virus (HSV-1 and HSV-2) in concentrations below 96 PPM. Limited human clinical studies have produced encouraging results.
The Company expects to continue testing TST against HIV and related opportunistic infections as funding allows.
Several patents and patents pending protect the intellectual property within the areas of infectious disease.
Potential: Infectious diseases have been on the increase worldwide and show no signs of abatement. Antibiotics have no affect on viruses, and bacteria are able to mutate so effectively that antibiotics have diminishing ability to inhibit bacterial growth. In developed countries, as many as 60% of hospital-acquired infections are caused by drug-resistant microbes. Over half of all hospitalized patients are treated with antibiotics. Antibiotics represent a significant portion of overall healthcare costs, accounting for between 20% and 50% of total hospital drug expenditures. TST may offer an alternative to antibiotics.
More people have died from HIV/AIDS over the last twenty years than from any other disease in human history. IMUSIL® (TST formulated for intravenous use) may offer an alternative to other anti-HIV drugs (which are highly susceptible to HIV mutation, can cause severe side effects in patients, require daily dosages, and are very costly). Currently, over 40 million people worldwide suffer from this pandemic, mostly outside the US. Estimates show that a global campaign against the epidemic needs $7-10 billion annually for an effective response in low- and middle-income countries.
Because IMUSIL operates on an entirely different principle from other drugs (including antibiotics and antiretroviral drugs), the Company’s compounds may offer an important alternative in the global fight against infectious diseases.
Next: Outside the US, two (2) clinical trials will be conducted in the coming months using IMUSIL against HIV/AIDS. Based on further documentation of IMUSIL’s efficacy, the Company hopes to receive approval from Ministries of Health in selected countries outside the US for IMUSIL treatment.
Next steps for infectious diseases also include ongoing pre-clinical and clinical research, regulatory new drug application, expanding the medical advisory and management group, and exploring potential strategic alliances.
For additional information, please contact us.
Status: A leading independent laboratory tested the effect of TST in-vitro on cultures of a variety of cancer cell lines, including human breast, colon, kidney, leukemia, liver, lung, lymphoma, melanoma, pancreas, prostate and stomach. Results from multiple testing revealed the low-concentration ability of TST to destroy these cancer cells upon contact.
Additional independent testing with TST also documented the compound’s ability to inhibit the production of cervical and mammary cancer cells. Subsequent testing has confirmed TST’s ability to covalently bind with cancer protein and destroy cancer cells. Marantech also contracted for an independent dermatological clinical analysis, including topical treatment of various skin and mucosal tumors with TETRASIL® (the company’s topical formulation). Promising preliminary results, verified by biopsy, were reported, including apparent elimination of cancerous cells in many patients with malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi’s sarcoma, early stage cases of Paget’s disease (nipple carcinoma), and cervical cancer. Results were encouraging and no adverse side effects were observed.
Several patents and patents pending protect the intellectual property within the areas of cancer therapeutics.
Potential: Scientists predict that by the year 2020 there will be 15 million new cases of cancer worldwide each year, and 10 million deaths. Cancer costs Americans alone more than an estimated $107 billion annually. TST systemic and topical therapeutic products may offer a significant alternative to existing cancer therapies.
Next: The Company is exploring strategic alliances and licensing agreements for funding and development of the company’s EJC technology for cancer therapeutics.
SKINCARE & TOPICAL SOLUTIONS
Aidance Skincare & Topical Solutions (a division of Marantech) is focused on fully developing the Company’s EJC technology for the treatment of non-cancerous skin conditions and diseases, including commercializing the division’s topical ointment (Tetrasil®).
Status: Independent laboratory and clinical studies commissioned by Marantech indicate that topically applied TETRASIL ointment may lead to improvements in a range of infection-related skin conditions (bacterial, viral, fungal), including cold sores, genital herpes, conjunctivitis, chickenpox, shingles, diabetic leg and foot ulcers, dermal tuberculosis [mycoplasma] and ringworm. Clinical studies also indicate that TETRASIL ointment may promote healing of skin conditions that are neither cancerous nor infection-related, including atopic dermatitis (eczema), psoriasis, poison ivy, and third-degree burns, apparently by both disinfecting the area and triggering an increase in the production of new, healthy skin tissue.
In multiple tests, TETRASIL has proved to be non-toxic. Limited human use of TETRASIL by over 500 patients with some of the above-named skin conditions has produced impressive results and strong testimonials.
Several patents and patents pending protect the intellectual property topical applications of EJCs.
Potential: Several viral, bacterial, fungal and other skin conditions present vexing challenges for the medical community and patients, and TETRASIL may offer an important and timely solution.
107 million people worldwide suffer from Genital and Oral Herpes. In the last two decades, genital herpes has doubled among white adults in their 20s while increasing fivefold among white teenagers, according to the U.S. Centers for Disease Control and Prevention. Now, about one in five teens and adults (some 45 million Americans) has the disease. A recent study estimates that 49 percent of women aged 15 to 39 will be infected with herpes simplex virus type 2 by 2025 if present trends continue. The associated medical costs would rise to $2.7 billion in 2025, from $1.8 billion in 2000. Initial clinical studies and anecdotal reports indicate that TETRASIL is effective against herpes and may offer a viable alternative to current medications.
The wound care market is a $10 billion worldwide industry. In the US alone, this market was estimated to be about $3.7 billion in the year 2000, with a compounded annual growth rate of about 3%. Market data for 2001 indicate that with an estimated 6.6 million patients nationally having pressure ulcers, an estimated $5 billion is spent annually for treatment. The two main types of chronic bacterially induced wounds of concern to the Company are diabetic foot ulcers and decubital ulcers (pressure ulcers, bed sores, etc.). This is a larger market than burns or traumatic and surgically induced wounds combined. In clinical studies and patient testimonials, TETRASIL has shown efficacious results against these types of ulcers.
Next: Clinical studies for TETRASIL will continue in 2003 at selected hospitals inside and outside the US. Current pending studies are focused on pressure ulcers (bedsores) and topical human papilloma virus (HPV) and/or genital warts infection.
Sales of TETRASIL in the US have already commenced. TETRASIL is currently sold without FDA approval as a no-claim product (www.tetrasil.com). Outside the US, the Company has begun shipping TETRASIL in collaboration with key distribution partners. Approval of TETRASIL, either as a cosmetic or pharmaceutical, in selected countries outside is expected to generate modest to significant income within the next few years.
Additional next steps include ongoing laboratory and clinical research, continued commercialization of TETRASIL, FDA new drug application, as well as ongoing application with foreign ministries of health for approval of TETRASIL, and expanding the medical advisory and skincare management group.’
I could not find anywhere to purchase Imusil online, but it may be possible. A Dr Antelman, the doctor who patented Tetrasil/Imusil as a cure, works with Marantech who used to sell Imusil. Rumour has it that they don’t sell it now: apparently they have to test it, so it cannot be released. Dr Antelman has been said to be under a lot of pressure by the authorities, as does anyone who comes up with anything positive and life-enhancing for the masses. Aidance Products, an offshoot of Marantech do sell Tetrasil online: see www.aidanceproducts.com. Tetrasil is for topological (external) use I understand. Someone wrote online that you might be able to get hold of Tetrasil and get a doctor to extract it and inject it. But I have no idea if this is possible or safe. I am looking it to this and will do an update if I come up with anything.
A friend of mine how is HIV positive started taking the Miracle Minerals Solution called MMS2. He said that within 4 months, his viral load reduced from 325000 to 35000 and his physical energy is returning. This is available from http://www.mineral-solutions.net.
We are also going to try to get hold of some Imusil for him to try. I’ll keep you posted if we succeed, and what the outcome is.